Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02243267 · ClinicalTrials.gov registry record
GI SPORE Colon Biosample Protocol
A clinical trial of Colon Cancer and Rectal Cancer, sponsored by University of Michigan.
- Completed
- Registry status
- 115
- Enrollment target
- 1
- Study location
NCT02243267: Completed study of Colon Cancer and Rectal Cancer, sponsored by University of Michigan.
NCT02243267 is a study of Colon Cancer and Rectal Cancer that has completed, run by University of Michigan. The registered enrollment target is 115 participants, below the 4,455-participant average among 97 other Colon Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02243267, a study of Colon Cancer and Rectal Cancer, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- 115 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators are creating a data and specimen repository to study causes , early detection, prevention and treatment of colon and rectal cancer. The investigators are collecting data and specimens (blood, stool, urine and tissue) from people who have colon or rectal cancer, or who are risk for developing colorectal cancer or had normal colonoscopies. Data and samples are held in the repository until there are enough to be used for a large study or until there are new techniques that can be used to test them. The GI SPORE Program at the University of Michigan maintains a repository of specimens for colorectal diseases that the investigators hope will help fuel new research. The investigators hope that this work may lead to new treatments or earlier detection of colorectal cancer or improved diagnosis and treatment of other colon and rectal diseases.
Primary Outcome
To create a longitudinal biorepository from individuals with colorectal cancer, those who are high risk for developing colorectal cancer, and screened, endoscopically normal controls including a reference set of well annotated, pathologically confirmed tissue, plasma, serum, and white blood cell biosamples and corresponding demographic, risk, and clinical treatment data for improved colon cancer detection.
Conditions Studied
Interventions
- OTHER sample collection
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2014-09 |
| Est. Completion | 2017-08-31 |
What the finished NCT02243267 record still lists
NCT02243267 is an observational study that tracks outcomes without assigning an intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 4,455-participant average among 97 other Colon Cancer trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Colon Cancer appearing as the primary indexed condition, and to 1 intervention - of which sample collection is the first listed.
NCT02243267 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT02243267 about?
NCT02243267 is a clinical study titled "GI SPORE Colon Biosample Protocol". The investigators are creating a data and specimen repository to study causes , early detection, prevention and treatment of colon and rectal cancer. The investigators are collecting data and specimens (blood, stool, urine and tissue) from people who have colon or rectal cancer, or who are risk for ...
What is the current status of trial NCT02243267?
This trial is currently completed. The enrollment target is 115 participants. The study started on 2014-09. Estimated completion is 2017-08-31.
What conditions does trial NCT02243267 study?
This clinical trial studies the following conditions: Colon Cancer, Rectal Cancer.
What interventions are being tested in trial NCT02243267?
The interventions under investigation include: sample collection (OTHER).
Who is sponsoring clinical trial NCT02243267?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02243267 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colon Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02243267's enrollment target sits among peer trials
115 47th of 97 higher than 50 of 97 other Colon Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colon Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
-
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia